NCT04445311.

Study name	Ivermectin in treatment of COVID‐19
Methods	Trial design: open‐label RCT with 2 parallel arms Type of record: trial register entry Sample size: 100 Setting: outpatient Country: Egypt Language: English Number of centres: NR Study purpose (treatment, prevention): treatment Trial registration number: NCT04445311 Date of registration: 24 June 2020
Participants	Inclusion criteria People with confirmed COVID‐19 during period of the study aged > 18 years Exclusion criteria Refusal to participate Pregnant or lactating Hypersensitivity to ivermectin Receiving any drug that interacts with ivermectin
Interventions	Details of intervention Type and dose: ivermectin for 3 days, no information on dosing scheme Route of administration: oral Treatment details of control group No treatment except standard of care Concomitant therapy: standard of care (no details provided) administered in both study arms
Outcomes	Primary study outcome Time to be symptom free within 21 days Relevant review outcomes planned Time to be symptom free within 21 days Need for hospital admission within 21 days Mortality at 30 days Additional study outcomes Need for hospital admission within 21 days Need for mechanical ventilation within 21 days Length of stay within 30 days Mortality at 30 days
Starting date	31 May 2020
Contact information	Waheed Shouman, MD Zagazig University Sharkia 44519 Egypt shouman66@gmail.com
Notes	Recruitment status: recruiting Prospective completion date: August 2020 Planned completion date more than 6 months ago: yes Date last update posted: 24 June 2020 Sponsor/funding: Zagazig University